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A recent study demonstrated an association between the Porphyromonas gingivalis (Pg) 
infection and the progression of ESCC (Gao et al., 2016). However, how Pg infection 
affects the nature of ESCC remains unknown. We examined the effects of Pg on the 
proliferation and chemotherapy drug-induced apoptosis of ESCC cells and elucidated the 
signaling molecules involved in these processes. 
 
Method:  Apoptosis and cell proliferation were tested using Flow cytometry and 
Tetrazolium salt based proliferation assays respectively. Western Blot was utilized to 
detect the protein expression. CDK2 and Cyclin E were knocked down in the ESCC cells 
through transfection. Unpaired T-test and ANOVA with post hoc Tuckey test was used to 
analyze relevant data (p<0.05). 
 
Results: Pg enhanced the proliferation and reduced the chemotherapy drug-mediated 
apoptosis of ESCC cells possibly through Cyclin E-CDK2 pathway and Caspase-3 
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1.1 Esophagus Squamous Cell Carcinoma 
 
1.1.1 Esophagus - Basic Anatomy and Histology 
 
Esophagus, also commonly referred to as food-pipe, is a tube-like organ that connects the 
pharynx and stomach. In adults, it is about 18-26 cm long. It starts at the 
pharyngoesophageal junction at the C5-C6 level and descends passing through the 
diaphragmatic hiatus at T-10 to end at the cardia of the stomach at T11 level. Both entry 
and the exit is “guarded by” upper and lower esophageal sphincters respectively. 
  
The wall of the esophagus is divided into- the mucosa, which lines the lumen; submucosa, 
muscularis propria, and the outermost adventitia. Unlike other gastrointestinal tract organs, 
the esophagus lacks an outer serous layer. This allows an easy spread of a tumor and makes 
it surgically harder to treat. A non-keratinized stratified squamous epithelium line the 
mucosa of the esophagus underneath which, there is a thin layer of connective tissue- 
lamina propria and a muscularis mucosae. Muscularis mucosae have irregularly arranged 
smooth muscle fibers. It grows in thickness distally. The submucosa layer contains glands 
as well as immune cells, vascular network (Heller’s plexus), nerve cells (Meissner’s 
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Plexus), etc. Muscularis propria is majorly composed of muscles. While the proximal half 
is richer in skeletal muscle fiber, distally it is composed primarily of smooth muscle. In 
between, where a mixture of both is seen, is called the transition zone (Kuo & Urma, 2006) 




Esophageal carcinoma is lethal. Esophageal cancer was the eighth most common cancer 
worldwide, comprising 3.2% (456,000 cases) of the new cancer burden, and ranked sixth 
in mortality with an estimated 4.9% (400,000 deaths) of cancer deaths. Esophageal cancer 
is estimated to be the eleventh leading cause of cancer death in the United States between 
2009-13. Esophageal patients are estimated to have poor survival with an overall ratio of 
mortality to the incidence of 0.88. An estimated 80% of the primary esophageal neoplasms 
are malignant (Pickens & Orringer, 2003). Of the estimated 456,000 cases, an estimated 
398,000 (87.28%) were squamous cell carcinoma while remaining were adenocarcinoma 
and other cancers. (Arnold, Soerjomataram, Ferlay, & Forman, 2015). The global incidence 
of esophageal squamous cell carcinoma was 5.2 per 100,000 with a global, male to female 
ratio at 2.7 (Bray, Ren, Masuyer, & Ferlay, 2012.) (Ferlay et al., 2013).  
 
It exhibits a marked geographic variation in incidence. Areas with notably higher incidence 
include China, South America, western Europe, southern Africa, Japan and regions of 
former USSR. Within these regions, there are pockets where incidence can be 10 to 50 
times higher. Such areas include northern and central China, southern Thailand, northern 
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Italy, mountainous regions of Japan, coastal parts of Iran and certain French provinces. In 
the United States, the District of Columbia and the coastal regions of the southern states 
reported the highest incidence. ESCC has a higher incidence in the urban areas of the 
United States and is particularly common in African-American men, with an overall 
incidence of approximately 3 to 4 per 100,000 people (Cook, 2011). The incidence of 
ESCC increases with age and peaks in the seventh decade of life. Around 30% of the 
patients exhibit metastasis at the time of presentation, and 30 percent have regional cancer 
at the time of undergoing primary surgery (Y. Zhang, 2013) 
 
The incidence of esophageal adenocarcinoma is on the rise in Europe. In North America, 
the United States and Canada have the highest incidence rates. Its rate of incidence is 
highest when compared to any other type of cancer (Pickens & Orringer, 2003). In 1975, 
esophageal adenocarcinoma affected four people per million, in 2001 this equation 
changed to 23 people per million making it the fastest growing variant of cancer in the 
United States.  In the 70s, esophageal squamous cell carcinoma (ESCC) was responsible 
for more than 90% of the esophageal carcinoma cases in the United States. However, for 
some unknown reasons, Adenocarcinoma has overtaken it, representing about 80% of the 
reported cases (Napier, Scheerer, & Misra, 2014). 
 
1.1.3 Types of Esophageal Cancers 
 
The two most common types of esophageal carcinoma are esophageal squamous cell 
carcinoma and esophageal adenocarcinoma. There are other types of esophageal cancer too 
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including lymphomas, rhabdomyosarcoma, melanoma, etc. However, they form a tiny 
percentage of the overall reported cases. 
 
1.1.3.1 Esophageal Squamous Cell Carcinoma. 
 
ESCC is associated with the esophageal middle third. It produces symptoms like difficulty 
in swallowing and loss of hunger that leads to weight loss. It arises from the squamous 
lining of the esophagus. In most cases, the patients suffered from chronic esophagitis.  
 
1.1.3.1.1 Histopathology of ESCC 
 
ESCC can show variable differentiation. A well-differentiated ESCC show keratin pearls, 
cell keratinization, intracellular bridges, etc. Poorly-differentiated ESCC lack these 
features and is determined to be of epithelial in origin by its location in situ, the presence 
of IEN (Intraepithelial dysplasia), the pattern of infiltration, using immunohistochemical 
markers like CK5/6 or p63, etc. Moderately-differentiated ESCC show intermediate 
features (Shilpa Jain & Dhingra, 2017). 
 
1.1.3.2 Esophageal Adenocarcinoma 
 
Esophageal adenocarcinoma is most often related to obesity, GERD, Barrett’s esophagus 
etc. It arises from the glandular portion of the esophageal lining. It is believed thatthe 
gastrict contents irritate the mucosal lining leading to the disease. Often a carcinoma in the 
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lower third of the esophagus most likely is an esophageal adenocarcinoma.  In some cases, 
they might occur next to ESCC giving rise to something called a Collision tumor (Maleki, 
Shekarriz, Nosrati, & Orang, 2015).  
 
1.1.3.2.1 Histopathology of EAC 
 
EAC can present as an ulcerative or exophytic mass. They are gland forming tumors with 
tubular, tubulopapillary or papillary growth patterns. A well-differentiated tumor shows 
more than 95% gland formation, moderately-differentiated shows anywhere between 50% 
to 95% gland formation. Poorly-differentiated tumor has less than 50% of glandular 
formation (Shilpa Jain & Dhingra, 2017). 
 
1.1.4 Risk Factors for ESCC 
 
Cigarettes, obesity, red meat, alcohol, tobacco-smoking, opium consumption, drinking hot 
beverages, poor oral health, low intake of fresh fruit and vegetable and low socioeconomic 
status is associated with a higher risk of esophageal squamous cell carcinoma (Y. Zhang, 
2013). ESCC risk increased with consumption of alcohol, with higher consumption 
corresponding to the higher risk of the disease. The incidence of ESCC dramatically 
increases in the presence of any factor that causes chronic irritation and inflammation. 
Consumption of alcohol and smoking promotes inflammation of the esophagus, but when 
done together they have a synergistic effect. The effect supposedly doubles than their sum 
individually. The relative risk of men who used both heavy tobacco and alcohol was 35.4 
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in white males and 149.2 in black males (Brown et al., 1994). Though studies are underway 
to understand the possible mechanism behind the process it is believed that the alcohol acts 
as a solvent for the carcinogens present in the tobacco smoke, and allow them easy access 
inside the esophageal epithelium (Napier et al., 2014). Consumption of hot beverages and 
pickles have been implicated as a possible risk factor too, but the evidence in this regard is 
limited.  
 
Lack of fresh fruit and vegetables and micronutrient deficiency is a risk factor for the 
disease (Y. Zhang, 2013).  Plasma riboflavin levels have been correlated with prognosis as 
well as risk. Other micronutrients like -carotene, vitamin-E, and selenium said to have 
reduced mortality. Exposure to chemicals (polycyclic aromatic hydrocarbons and 
nitrosamine) is seen as a cause of ESCC (Napier et al., 2014). Studies in northern Iranian 
population linked increased urinary levels of PAH metabolites with increased risk. Similar 
studies in China and Brazil yielded similar results (Liang, Fan, & Qiao, 2017). 
Carcinogens, and a potential causative agent of ESCC, nitrosamines, have been found in 
some salted vegetables and certain preserved fish varieties (Napier et al., 2014). 
 
1.1.5 Bacteria and Esophagus 
 
It was Yang et al. who first distinguished between the microbiota of a healthy and a 
diseased esophagus. They noticed a shift from Gram-positive rich microbiota dominated 
by Firmicutes in healthy esophageal epithelium to a more Gram-negative rich microbiota 
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(Veillonella, Prevotella, Bacteroidetes, Haemophilus, Neisseria, Campylobacter, 
Fusobacteria, etc.) in mucosa associated with GERD related esophagitis and BE. 
 
Works to look into the microbiota associated with esophageal cancer has been there for 
three decades. The earlier studies suffered from a severe limitation of culture-dependent 
approach, the absence of control groups and due to the lack of histological differentiation 
between EAC and ESCC. Narikiyo et al. were among the first to characterizes the 
microbiota of esophageal cancer patients. However, it is unclear if the patients were 
suffering from ESCC or EAC or both. Their study demonstrated unusual domination by 
Treponema denticola, S. mitis, and S. anginosus in esophageal cancer tissue. 
 
The presence of Campylobacter concisus, which is seen in high numbers in GERD and BE, 
play a role in EAC progression. C. concisus colonization is believed to cause inflammatory 
dysbiosis which drives EAC. However, their lower prevalence from actual EAC lesion 
raises questions. Some authors have tried to explain this phenomenon using driver 
pathogen model. 
 
Further, recent studies have suggested that poor microbial diversity promotes esophageal 
squamous dysplasia.  A decrease in abundance of Lautropia, Bulleidia, Catonella, 
Corynebacterium, Moryella, Peptococcus and Cardiobacterium was noted. Chen et al. 
reported a relative abundance of Prevotella, Streptococcus, and Porphyromonas in ESCC 
cases (Di Pilato et al., 2016; Peters et al., 2017; Chen et al., 2015). A recent epidemiological 
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study has shown the Porphyromonas gingivalis, a gum bacterium to be associated with 
ESCC. 
 
1.1.6 Routes of Esophageal Cancer Spread 
 
Esophageal cancer is notoriously aggressive. It can spread through direct invasion, 
lymphatic spread, and hematogenous metastasis. The esophagus is lacks a serous layer like 
other GI tract organs that contributes to local extension of esophageal cancer. In the 
absence of an anatomical barrier, cancer quickly spread into nearby structures of neck and 
thorax (Kuo & Urma, 2006) (Yazaki & Sifrim, 2012). 
  
The esophagus has a rich lymphatic supply. The lymphatics in the upper half of the 
esophagus carry the lymph upwards while the lower half carry it downwards. All the 
lymphatics of the organ are well connected. It results in the spread of the secondary tumor 
in any direction (Napier et al., 2014) 
 
1.1.7 Treatment Modalities 
 
There are three primary treatment modalities for treating ESCC. These are– surgical 
approach, chemotherapy, and radiological treatment. The stage of cancer determines the 
treatment modality or the combination of the treatment modalities to be employed. 
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Surgical approach involves esophagectomy. Different approaches are prescribed 
depending on the extent, the location of the tumor, etc. Chemotherapy and radiotherapy 
are other critical modalities of treatment. According to the National Comprehensive 
Cancer Network 2013 guidelines a triple therapy drug regimen that includes 
paclitaxel/carboplatin, cisplatin/fluoropyrimidine, and oxaliplatin/fluorouracil. The 
recommended radiation dose is 41.4-50.4 Gy (Napier et al., 2014). 




1.2.1 A Brief Introduction to Periodontitis 
 
American Association of Periodontology defines Periodontium as ‘the tissues that invest 
and support the teeth including the gingiva, alveolar mucosa, cementum, periodontal 
ligament, and alveolar supporting bone’ (“PERIODONTIUM - AAP Connect,” n.d.). The 
disease that inflicts these structures are Periodontal Diseases, of which gingivitis and 
periodontitis are the most common. Gingivitis is limited to the gums, while periodontitis is 
more extensive, and involves underlying bone and other structures of the periodontium. 
Gingivitis is seen during the initial phases as the inflammation of the gingival tissue. Since 
it involves soft tissue structures and is seen during early phases of the Periodontal disease, 
it is reversible in most of the cases.  
 
‘Periodontitis is characterized by microbially- associated, host-mediated inflammation 
that results in the loss of periodontal attachment’. Periodontitis destroys tooth-supporting 
structures that lead to gingival recession, periodontal pocket formation and the loss of the 
surrounding alveolar bone. As a result, the tooth becames mobile and left untreated will 
lead to exfoliation. The disease process involves activation of the molecular pathway that 
leads to activation of host mediators that ultimately causes loss of periodontal ligament 
fibers, apical migration of junctional epithelium and apical spread of bacterial biofilm 
(Tonetti, Greenwell, & Kornman, 2018).  
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However, this definition of periodontitis came under severe criticism in 2017 because of 
limitations in its applicability. Traditionally, attachment loss is determined by 
circumferential assessment of the erupted dentition using a standardized periodontal probe 
in conjunction with radiographical evidence of marginal bone loss. It is to be noted that 
some diseases other than periodontitis can cause loss of attachment and radiographical 
evidence have limited application. Limitation of radiographs is due to the fact they are not 
specific and may not register bone loss due to mild to moderate periodontitis.  
 
It created a need for a more patient-based definition of periodontitis. It defines a periodontal 
case as Interdental Clinical loss of Attachment (CAL) is detectable at ≥ 2 non-adjacent 
teeth, or buccal  or  oral  CAL ≥3  mm  with  pocketing >3mm is detectable at ≥2 teeth, 
and the observed CAL cannot be a byproduct of non-periodontal causes such as 1)  gingival  
recession  of  traumatic  origin; 2) dental caries extending in the cervical area of the tooth; 
3) the presence of CAL on the distal aspect of a second molar and associated with 
malposition or extraction of a third molar, 4) an endodontic lesion draining through the 
marginal periodontium; and 5) the occurrence of a vertical root fracture.  
 
The new classification is aimed at 1) Identification of a patient as a periodontitis case, 2) 
Identification of the specific form of periodontitis, and 3) Description of the clinical 
presentation and other elements that affect clinical management, prognosis, and potentially 




1.2.2 Overview of the Epidemiology of Periodontitis 
 
Severe periodontitis is ranked at six most prevalent condition affecting 11% of the global 
population (Marcenes et al., 2013). It affected 573 million people worldwide leading to 
276 million patients to lose their teeth (Kassebaum et al., 2017). According to estimates, 
over 47% of adult US population (30 years and older) suffers from periodontitis. Around 
30% of this population suffers from moderate periodontitis while about 8.5% suffers from 
severe periodontitis.  For adults over 64 years of age, 64% of them suffers from moderate 
to severe periodontitis. Epidemiological studies show that periodontitis has a predilection 
towards older individuals; males; Mexican Americans; individuals with poor economic 
status and smokers. (Eke, Dye, Wei, Thornton-Evans, & Genco, 2012). 
 
1.2.3 Classification of Periodontal Diseases 
 
In the 1989 Periodontitis was classified based on the age of onset and rate of progression 
as Prepubertal, Juvenile, Adult and Rapid-Onset. In 1993, this classification was simplified 
as Adult and Early-onset periodontitis. However, in the absence of evidence, this 
classification was abandoned in 1999. The 1999 Classification system of Periodontal and 
Peri-implant diseases classify periodontal diseases based on the unique feature of different 
phenotypes into four different forms as 
 Necrotizing periodontitis 
 Aggressive Periodontitis 
 Chronic Periodontitis 
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 Periodontitis as a manifestation of systemic diseases 
The primary objective of this classification was to differentiate the more common forms of 
periodontitis, chronic and aggressive periodontitis, from other rarer conditions like the 
necrotizing form and rare genetic disorders. This classification devised major and minor 
criteria and by default if the case of periodontitis did not satisfy the criteria for the 
aggressive form it was considered to be the chronic variant. However, in practice clinicians 
faced significant challenges as many of these criteria overlapped Furthermore, aggressive 
and chronic periodontitis have similar pathophysiology with little evidence that both are 
distinct disease and not variants of the same disease. (Tonetti et al., 2018). 
 
The 2017 World Workshop on the Classification of Periodontal and Peri-implant Disease 
and Conditions proposed a new classification system based on pathophysiology. According 
to the new classification, periodontal diseases are classified on the basis of pathophysiology 
as Necrotizing Periodontal diseases, Periodontitis and Periodontitis as a manifestation of 
systemic diseases. For Periodontitis that arose a direct manifestation of systemic diseases, 
it follows the classification of the primary disease as laid down by the international 
statistical classification of disease and related health problem codes (Tonetti et al., 2018). 
 
Necrotizing ulcerative periodontal diseases is a group of disorders with similar etiologies 
comprising of necrotizing ulcerative gingivitis, ulcerative periodontitis, and necrotizing 
stomatitis. These different diseases are different stages of the same disease with various 
extent of destruction. Necrotizing ulcerative gingivitis (NUG) is limited to the gingival 
tissue. It is often referred to as trench mouth disease, as it was very prominent among the 
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soldiers fighting the World War II trenches. In cases where the NUG extends into the 
underlying periodontal apparatus resulting in the loss of bone and CAL, it is classified as 
Necrotizing ulcerative periodontitis (NUP). If left untreated it may continue to involve 
deeper tissues beyond the mucogingival line to include lip, cheek or tongue and is referred 
to as Necrotizing stomatitis (Hu, Kent, Lennon, & Logan, 2015; Miranda-Rius, Brunet-
Llobet, & Lahor-Soler, 2018). 
 
At the beginning of the 20th century due to lack of evidence against any specific bacteria, 
it was not considered as a specific infection but as an opportunistic one that is caused by 
indigenous oral microflora. Around the same time, other theories like, vitamin-deficiency 
theory and debilitating theory, were put forth. Recent studies have shown that in these 
cases, there is an imbalance in the normal oral flora with reduced diversity. There was an 
increase in Provetella genus with loss of Capnocytophaga and Fusobacteria genera. 
However, increase Provetella is often associated with other pathogens and has never been 
reported as a primary causative agent. It is likely that Provetella flourishes in the disease 
condition and may not be the actual cause of the disease (Srour, Marck, & Baratti-Mayer, 
2017). 
 
1.2.3.1 Classification of Periodontitis  
 
Older classification systems did not address the past impact of the disease on the patients, 
treatment approach, and management, or the progression of the disease. The new 
classification classifies the Periodontitis into Stages and Grades, like TNM staging in 
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Cancer. The stages of the disease record the severity, treatment complexity and the extent 
and distribution, whereas the grading looks at the progression of the disease, associated 
risk factors, systemic impact of periodontitis and biomarkers. Though attempts were made 
by the earlier systems to record the severity of the disease, there were limitations. With 
improved techniques clinicians are able better manage certain conditions which affect its 
severity. Another limitation was, with the loss of the most diseased tooth led to an apparent 
decrease in the severity of the disease. There was a need to address the complexity of 
management of a case. The inclusion would help the clinicians to decide on the competence 
and experience level required to manage the case. It is especially helpful in the case of 
general dentists as it makes it easier for them to decide when to refer the patient.  
 
The staging of the disease envisages helping identify the severity and extent of the disease 
based on currently measurable extent of destruction of the tissue that is attributable to 
periodontitis and to assess the complexity of different factors that may determine the 
complexity of future treatment plan. The grading mechanism aims at estimating future risk 
of periodontitis progression and responsiveness to standard therapeutic principles, to guide 








1.2.3.1.1 Stages of Periodontitis 
 
Stage I  
 
It represents the initial stages of the disease and the early stages of attachment loss with a 
maximum interdental CAL of 1 to 2 mm and/or a maximum probing depth equal to or less 





It represents established periodontal case. The clinical management of the case remains 
relatively simple. An interdental CAL of 3 to 4 mm is seen and/or a maximum probing 





It represents severe periodontitis which has produced significant damage to the periodontal 
apparatus and had the potential for tooth loss. An interdental CAL of equal to or more than 
5 mm and/or a probing depth equal to more than 6 mm is seen. The bone loss extends to or 
beyond root mid-third and/or a vertical bone loss of 3 mm or more. There can also be 
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furcation involvement of class II or III or moderate ridge defect. Stage III cases have a 




It represents an advanced periodontitis case with extensive tooth loss. Patients have lost 5 
or more teeth due to periodontitis. It has all the characteristics of a Stage III periodontitis 
but has an added complexity due to the need for complete rehabilitation. 
 
The extent (localized or generalized) and the distribution(molar/incisor) cut across all the 
four stages of periodontitis  
 
1.2.3.1.2 Grade of Periodontitis 
 
It is to be noted that irrespective of the stage of the periodontitis it may progress at different 




It represents a slow rate of progression. In spite of the presence of heavy biofilm deposits, 
the progression of the disease is relatively slow. There is no bone loss over a period of 5 
years. The patient is a non-smoker and a non-diabetic and has a high sensitivity C reactive 




It represents a moderate of progression. The progression of the disease matches the amount 
of biofilm. There is a less than 2 mm of bone loss over a period of 5 years. Patients smoke 




It represents a rapid rate of progression. The amount of destruction far exceeds the amount 
of biofilm deposit. There is a bone loss of 2 mm or more over 5 years. The patient can be 
a smoker with consumption of above 10 cigarettes per day. The patient can be diabetic with 
HbA1c equal to more than 7% in patients. The hsCRP level exceeds 3 mg/L. 
 
In case there is a conflict between the criteria always a higher stage or grade defines the 
case (Tonetti et al., 2018). 
 
1.2.4 Theories of Periodontitis and the Emerging Role of Porphyromonas gingivalis 
 
Periodontitis is known to afflict humankind since the dawn of the civilization. Ancient 
records and paleopathological studies have shown gum diseases, and loosening of teeth are 
as old as humanity. The ancient Egyptians and Chinese describe periodontal diseases as an 
inflammatory condition. Hippocrates (460-335 B.C.) is seen describing this affliction in 
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his works. In later years, Hebrews, Romans, and Arabs all have tried to describe the disease 
and tried to provide the treatment for the same. 
 
Pierre Fauchard is credited with a modern description of the disease in his treatise Le 
chirurgien dentist. Fauchard identified calculus build-up as the cause of the disease and 
advised its removal using special instruments. He prescribed the use of dentifrices and 
mouthwashes to prevent the buildup calculus and advised splinting the loose tooth. An 
Englishman, John Hunter, proposed that the inflammation process in the gingiva as an 
important factor that causes the dissolution of the surrounding alveolar bone. Later on, 
Riggs in his article Pyorrhea Alveolaris placed the responsibility of the disease on calculus 
and other foreign bodies that made the tooth structure rough. Riggs was convinced that the 
disease was the byproduct of local factors(Löe, 1993). 
 
While the Localists like Riggs dominated the United States scene; Europeans increasing 
believed that nutritional deficiencies and imbalances, and other systemic conditions is 
caused by the periodontitis. This led to a localist versus generalist debate (Hujoel, Zina, 
Cunha‐Cruz, & Lopez, 2012).  
 
W.D. Miller in 1886 was the first to relate the oral diseases to germ theory. According to 
him, pyorrhea alveolaris was caused by various bacteria working together but none in 
particular. Hence, in essence, what Miller proposed over a 100 years ago can be interpreted 
as a multifactorial disease resulting from a nonspecific infection and disturbance of normal 
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host-microbe relationship. However, he did not put forth any substantial evidence 
supporting his case (Löe, 1993). 
 
In 1911, W. Hunter proposed focal infections theory which hypothesized that oral 
infections could act as a source of sepsis. He proposed the use of the gold crown, gold caps, 
gold bridges, etc. to build a “gold mausoleum to contain sepsis.” It led to the practice of 
removing teeth for no good reason other than the notion that periodontal lesion and necrotic 
pulp were life-threatening time bombs (Löe, 1993). 
 
Works of Waerhaug and others in the early 1950s re-introduced plaque into the picture. 
They demonstrated the importance of plaque as the etiological agent in periodontal disease 
and that by preventing plaque formation one can avoid periodontal disease. Epidemiolocal 
studies further bolstered this stand. This finding that periodontitis is an infectious disease 
change the treatment approach as well as led the search for the causative microorganism 
(Löe, 1993).  
 
1.2.4.1 Non-specific plaque theory 
 
It was believed that poor oral hygiene led to gingivitis which later progressed to 
periodontitis. It was proposed that in the absence of proper oral hygiene the gingival crevice 
gets colonized by complex indigenous microflora causing a non-specific inflammation of 
the gingiva. The sub-gingival plaque was believed to be a downgrowth of supragingival 
plaque. A combination of indigenous bacteria, rather than a single species, produced 
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gingivitis that progressed to periodontitis (Theilade, 1986). This is referred to as Domino 
theory. In order to prevent periodontitis, it was essential that plaque must be controlled to 
prevent other two conditions from developing (Hujoel et al., 2012). However, unlike 
gingivitis which is closely related to bacterial colonization and level of plaque 
accumulation, periodontitis has more specific and complicated etiology. This theory 
focused on the quantity of plaque rather than its quality and thus was unable to explain 
periodontitis cases with minimal plaque levels. 
  
1.2.4.2 Specific Plaque theory 
  
Specific Plaque proposed that a specific ‘complex of organisms’ in responsible for 
periodontitis. The ‘Red complex’ was indicated to be a major player in periodontitis. This 
complex was composed of P. gingivalis.; T. forsythia and T. denticola (Socransky, 
Haffajee, Cugini, Smith, & Kent, 1998). This hypothesis proposed a more targeted 
approach. It proposed the use of antimicrobials as an effective measure to counter 
periodontitis (Nisha, 2017). 
 
1.2.4.3 Ecological Plaque Hypothesis 
 
This theory proposed that, in healthy individuals, the oral bacterial population remains 
relatively stable. This relative stability was attributed to synergistic and antagonistic 
microbial interactions. However, an imbalance in this homeostasis leads to a shift in the 
balance of microflora, thereby predisposing sites to disease. Changes in local environment 
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influence the occupant microflora population. It was proposed that disease can be treated 
by targeting the offending organism as well as by interfering with the process that led to 
the loss of homeostasis (Marsh, 1994). 
 
1.2.4.4 The Polymicrobial Synergy and Dysbiosis Model of Periodontal Disease 
Etiology 
 
The colonizing bacteria organize themselves in a physiologically compatible 
communicative community. The introduction of a keystone pathogen (a pathogen with a 
disproportionately large effect on its environment relative to its abundance) like P. 
gingivalis alters the dynamics of the community. Communication between P. gingivalis 
and other organisms which in general acts as commensals, accessory pathogen (an 
organism that while commensal in a particular microenvironment, nonetheless supports or 
enhances the virulence of another organism), etc. facilitate synergy and causes 
pathogenicity. This new community of organism is called as a dysbiotic community. As 
this dysbiotic community continues to grow, it stimulates an inflammatory response. In a 
susceptible host, this inflammatory response is often frustrated and misdirected which leads 
to excessive destruction of host tissue facilitating the flourishment of an inflammophilic 
community which sustains itself on the inflammation derived breakdown-nutrients. 
However, in later stages, the driver bacteria (P. gingivalis) is out-competed by passenger 
bacteria (Lamont & Hajishengallis, 2015). However, it must be kept in mind that the 
current model of PSD is based on a mouse model. P. gingivalis is not a natural inhabitant 
of mouse oral cavity and that at the time of writing there were no human studies to support 
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the PSD model. How P. gingivalis presence leads to periodontitis remains to be fully 
understood, but there is no denying the fact that prefers to exist in a plaque around the teeth 
in the subgingival sulcus of the human oral cavity. When seen in the context of Gao et al. 
study it indicates that eradication of oral pathogen could potentially contribute to a 
reduction in the overall ESCC burden (Gao et al., 2016).  
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1.3 Porphyromonas gingivalis 
 
1.3.1 Introduction to Oral Microbiota Scene 
 
It is estimated that the oral cavity of a healthy human adult harbors at least six billion 
bacteria with representation from over 700 species (Aas, Paster, Stokes, Olsen, & Dewhirst, 
2005). Apart from bacteria, the oral cavity is home to various species of fungi mycoplasma, 
protozoa, and viruses. However, this diverse oral microbial community is more or less 
stable and is referred to as climax community. However, in a diseased condition like caries 
or periodontal diseases, an imbalance can be seen in the oral resident microbiota favoring 
potentially pathogenic microorganism (How, Song, & Chan, 2016a). 
 
1.3.2 Porphyromonas gingivalis  
 
 Porphyromonas gingivalis is a non-motile, asaccharolytic, Gram-negative, rod-shaped, 
obligate anaerobic bacteria (Bostanci & Belibasakis, 2012). It forms black pigmented 
colonies on blood agar plates. Porphyromonas gingivalis primarily occupies the 
subgingival sulcus in the human oral cavity with a reported frequency of 87.75% in patients 
with chronic periodontitis. However, different studies peg this number at different levels 
ranging from 40-100%. Some of the studies have shown a substantial increase in P. 
gingivalis at periodontitis sites with virtually low to no detection at plaque-associated 
gingivitis (How, Song, & Chan, 2016b). P. gingivalis is shown to be found in deep gingival 
pockets in a higher frequency than when compared to the shallow pockets. It metabolizes 
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amino acids for energy when sugar levels are low. It is said to be secondary colonizer 
owing to its obligate anaerobic nature (Bostanci & Belibasakis, 2012). It is often found to 
adhere to Streptococcus gordonii and P. intermedia. P. gingivalis is often associated with 
T. denticola and T. forsythia in advanced lesions. Further, in almost all the cases P. 
gingivalis antibodies were found to higher in periodontitis cases.  This evidence suggests 
Porphyromonas gingivalis is strongly associated with periodontitis (How et al., 2016a), 
and has been often described as a pathobiont (Cugini, Klepac-Ceraj, Rackaityte, Riggs, & 
Davey, 2013). A pathobiont is an organism which has a pathogenic potential. However, 
under normal circumstances lives as a symbiont. It is thought that Porphyromonas 
gingivalis is a natural inhabitant of the human oral cavity. However, a shift in the microbial 
composition is associated with its growth.  
 
Figure 1: Image of Gram-negative Porphyromonas gingivalis under 40X magnification. 
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 As discussed earlier, the PSD model hypothesize that P.  gingivalis interact with other 
members of the host microbiota and helps in the progression of the disease. 
 
1.3.3 Virulence Factor of Porphyromonas gingivalis 
 
Porphyromonas gingivalis contributes towards dysbiosis leading to an inflammatory 
onslaught. It possesses virulence factors which not only contributes towards its survival 
against host attack but also promote inflammation. Virulence factors may be defined as the 
constituents or metabolites of an organism which are essential in various stages of the life 
cycle and cause damage to the host.  The expression of these virulence factors is found to 




It forms the outermost layer of the organism and contributes towards its attachment to host 
tissues. Adherence to host tissue provides the organism a sort of environmental permanence 
and help it resist against the flushing action of saliva and gingival crevicular fluid (GCF). 
The chemical composition of the capsule is found to vary between strains of P. gingivalis. 
This difference is usually due to the composition of the sugar. P. gingivalis is known to 
display six capsular antigens (1-6) (Laine, Appelmelk, & van Winkelhoff, 1997).  
 
Highly capsulated strains are hydrophilic, lower in density and autoagglutination. It is 
thought capsule provides resistance against phagocytosis, perturbation of gingival 
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epithelial cells and decreased induction of neutrophils (Singh et al., 2011) (How et al., 
2016). P. gingivalis was able to modulate the immune response by reducing the production 
of interleukin-1 (IL-1), IL6 and IL-8. Capsule protects P. gingivalis against small anti-
microbial peptides like defensins.  P. gingivalis utilizes its capsular protein to interact with 
other bacteria like Fusobacterium nucleatum in its environment (Binder Gallimidi et al., 
2015). Capsule prolongs the survival of P. gingivalis and helps it escape inflammatory 




 P. gingivalis possess thin hair like proteinaceous structures which arises from the outer 
membrane of the bacterial cell. They vary in their length and can measure from 3-25mm.  
P. gingivalis expresses two distinct types of fimbriae on its surface- long or major fimbriae 
encoded by fimA gene and short or minor fimbriae encoded by mfa1 gene. 
 
The FimA protein can weigh from 40.5 to 49 kDa based upon the strain. There are six types 
of these fimbriae (Type I-V and Ib) based on the amino-terminal, and the DNA sequence. 
Type I stains like P. gingivalis ATCC 33277 are abundantly fimbriated, and Type IV 
strains are poorly fimbriated (W. Zhang, Ju, Rigney, & Tribble, 2011). 
 
Minor fimbriae are demonstrated to stimulate the production of IL-1, IL-1, IL-6, and 
TNF- by macrophages(Amano, Nakagawa, Okahashi, & Hamada, 2004). It is 
hypothesized that minor fimbriae are responsible animal bone resorption in animal models. 
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Fimbriae help P. gingivalis to bind and invade host cells such as host phagocytes, 
osteoclast, and epithelial cells. It also helps the bacteria to adhere to other commensal 
bacteria such as Streptococci gordonii, extracellular matrix proteins, and salivary proteins. 
Fimbriae adhere to cellular 51-integrin which causes rearrangement of actin cytoskeleton 
resulting in the internalization of the bacteria with the help of lipid rafts, dynamin, etc. 
There is emerging evidence relating the fimbriae with atherosclerosis progression by 
reducing regulatory T cells (Tregs) (How et al., 2016).  
 
1.3.3.3 Lipopolysaccharides (LPS) 
 
Lipopolysaccharide is a component of the bacterial outer membrane. It is a large molecule 
and over 10 kDa in size. It maintains structural integrity and controls the entry of molecules 
into the bacterial cell. It consists of a distal polysaccharide (O-antigen), a non-repeating 
core and a hydrophobic domain known as lipid A (endotoxin). Lipid-A is the innermost 
component and is biologically active (Sumita Jain & Darveau, 2010) 
 
P. gingivalis LPS has multiple Lipid-A moieties. The expression of Lipid-A structure can 
be manipulated by hemin concentration and temperature; as a result, PgLPS differs 
significantly under different environmental conditions. The two most predominant 
isoforms are a penta-acylated form (LPS1690) and tetra-acylated form (LPS1435/1449). The 
penta-acylated form predominantly activates TLR4 mediated NF-B signaling pathway 
whereas tetra-acylated form promoted the production of anti-inflammatory proteins (e.g., 
Annexin A2 and Annexin A6) (Herath et al., 2016). 
 29 
Lipid-A portion of the LPS is found to activate host inflammatory response and disrupt 
bone remodeling. LPS of P. gingivalis ‘paralyse’ the gingival epithelial cells limiting the 
production of IL-8. This is called chemokine paralysis (Darveau, Belton, Reife, & Lamont, 
1998). LPS inhibits osteoblastic differentiation and mineralization hence preventing 
healing of the periodontal tissues (How et al., 2016). 
 
Presence of circulating LPS promotes the production of metalloproteinases which is 
implicated in cardiac dysfunction (How et al., 2016). It also stimulates the production of 
thrombospondin-1, which stimulates the migration of monocytes (Gokyu et al., 2014). A 
recent fining by Ci et al. demonstrated the inhibitory effects of grape seed extract 
(proanthocyanidin) on P. gingivalis LPS (Ci, Chen, & Ou, 2015). Tormentic acid, on the 
other hand, is reported to inhibit LPS-induced inflammatory response in human gingival 




P. gingivalis primarily produces two distinct families of proteases- cysteine proteinase 
family and serine proteinase. The cysteine-proteinases cleave polypeptides at C-terminal 
after arginine or lysine residue. Two major cysteine-proteases produced by P. gingivalis 
are, Gingipain-R and K. Further, there are two types of gingipain R, RgpA and RgpB. 
Gingipain R cleaves arginine while K cleaves lysine (Bostanci & Belibasakis, 2012). These 
proteinases constitute 85% of the extracellular proteolytic activity of the P. gingivalis (de 
Diego et al., 2014). Rgp can degrade extracellular matrix, immunoglobulins, cytokines, 
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etc. It is also crucial for the maturation of the fimbriae. Gingipain can degrade fibrinogen 
and heme proteins which may promote bleeding and increase the availability of heme 
protein for bacterial growth. They degrade antibacterial peptides like -defensin, 
complement factors. They reduce the expression of CD14 resulting a hyporesponsive 
macrophage. Proteases are involved in the degradation of collagen, activation host matrix 
metalloproteinases, inactivation of plasma proteinase inhibitors, cleavage of cell surface 
receptors and deregulation of the inflammation. They also act as an additive to the growth 
of A. actinomycetemcomitans and T. forsythia (How et al., 2016) (Mysak et al., 2014). 
 
1.3.3.5 Outer Membrane Protein 
 
Porphyromonas gingivalis possess two cell membrane layers- the outer membrane and the 
inner membrane. These layers differ from each other in structure as well as composition. 
These two layers are separated from each other with a peptidoglycan rich layer called as 
periplasm. The outer layer is asymmetrical in structure and is bi-layered comprising of 
lipopolysaccharide rich outer portion and a phospholipid-rich inner portion. The inner 
membrane is a phospholipid layer with proteins. The bacterial cell membrane acts as a 
selective barrier. Of the two outer membranes is supposed to contribute more towards 
inflammatory response as it is the more exposed part when compared of the two. It helps 
P. gingivalis interact with other periodontal microflora and upregulate T helper cells to 




1.3.4 Porphyromonas gingivalis Beyond Periodontitis 
 
In recent years there is emerging evidence that P. gingivalis is not merely limited to 
periodontal diseases. Further, that the relationship between periodontal diseases and 
systemic diseases is not unidirectional. This discovery of this bidirectional relationship has 
fueled numerous studies in this direction. Porphyromonas gingivalis has been implicated 
in various diseases including cardiovascular diseases, atherosclerosis, cancer, Alzheimer’s, 
etc. (Mysak et al., 2014)  
 
Its involvement in various cancers in very interesting. With a rising number of cancer cases 
in recent times compounded with an almost ubiquitous presence of this organism demands 
immediate attention. 
 
1.3.5 Porphyromonas Gingivalis and Cancer 
 
Since the 1990s, there is accumulating evidence against Porphyromonas gingivalis as a 
mediator in the development of chronic diseases and oro-digestive cancers (Atanasova & 
Yilmaz, 2014). Tezal et al. demonstrated the association between periodontitis and the 
incidence of cancer of the oral cavity, oropharynx, and larynx with the strength of 
association greatest in the oral cavity followed by oropharynx and larynx (Tezal et al., 
2009). In a prospective study conducted on 405 pancreatic patients, it was found that 
patients with high levels of antibodies against Porphyromonas gingivalis ATCC 53978 
were 2-fold more likely risk of pancreatic cancer than individuals lower levels of these 
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antibodies (Michaud et al., 2013). In a prospective cohort study conducted on 361 incidents 
of pancreatic adenocarcinoma, Porphyromonas gingivalis increased the Odds Ratio of 
presence vs. absence to 1.16 (Fan et al., 2018).  
 
Porphyromonas gingivalis can invade gingival squamous cell carcinoma. A relatively 
greater invasion was seen in the case with poorly differentiated cells (Katz, Onate, Pauley, 
Bhattacharyya, & Cha, 2011). In a prospective study, Ahn et al. found oro-digestive 
cancer’s mortality is related to periodontitis and Porphyromonas gingivalis (Ahn, Segers, 
& Hayes, 2012). Porphyromonas gingivalis in the presence of human -defensins 
promoted cell proliferation in oral tumor cells (Hoppe et al., 2016). Porphyromonas 
gingivalis alters expression of the B7-H1 and B7-DC receptors in squamous carcinoma 
cells, which may help oral cancer cells from evading immune response (Groeger, Domann, 
Gonzales, Chakraborty, & Meyle, 2011).  
 
Porphyromonas gingivalis is capable of activating ERK1/2-Ets1, p38/HSP27, and 
PAR2/NF-kB pathways to induce proMMP9 expression. This proenzyme is later converted 
by gingipain, a protease produced by Porphyromonas gingivalis, which promotes invasion 
in oral squamous cell carcinoma (OSCC) cell lines (Inaba et al., 2014). It is shown to 
promote tumor growth by enhancing endothelial progenitor cell function and 
neovascularization through GroEL protein (Lin et al., 2015). It produces proteases like 
gingipain. Gingipain is found to affect the stability and function of SPINK6, a Kallikrein 
inhibitor. Gingipain promotes the activation of Kallikrein. Kallikrein is positively 
associated with tumor development and is clinically used as a tumor progression marker. 
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This indicated a possible mechanistic relationship between periodontal disease and tumor 
progression(Plaza et al., 2016).  
 
-Catenin pathway has also been suggested as a possible pathway for the promoting 
proliferation in the epithelial cells by Porphyromonas gingivalis (Zhou et al., 2015). In a 
separate study, Porphyromonas gingivalis and Fusobacterium nucleatum were found to 
enhance tumorigenesis of oral epithelial cells through Toll-like receptors (Binder Gallimidi 
et al., 2015). However, a previous study contradicts these findings (Park, Yoon, Jeon, Ahn, 
& Yoon, 2010). Ha et al. in a recent study pointed out the Porphyromonas gingivalis is 
capable of promoting epithelial-mesenchymal transition-like changes in oral squamous cell 
carcinoma (Ha et al., 2015). Further, they also found out that Porphyromonas gingivalis 
promoted invasiveness of OSCC via IL-8 and MMPs (Ha et al., 2016).   
 
All these evidence pointed that Porphyromonas gingivalis might also play a role in the 
progression of esophageal squamous cell carcinoma. The first direct evidence of the role 
of Porphyromonas gingivalis in esophageal squamous cell carcinoma was published in a 
study by Gao et. al. In their study, they showed that Porphyromonas gingivalis 
preferentially invaded esophageal squamous cell csqarcinoma when compared to healthy 
tissue. Epidemiological data suggested that Porphyromonas gingivalis was positively 
associated with various clinicopathological factors including differentiation, metastasis 
and overall survival rate (Gao et al., 2016). This is a significant finding as for the first time 
Porphyromonas gingivalis was linked to the progression of ESCC and the patient survival 
rate.  
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1.4 Cyclins and CDKs 
 
1.4.1 Introduction to Cell Cycle 
 
The cell cycle is the life story of cells. It comprises of stages through which the cell passes 
from one division to the next. A cell cycle beings after a cell has completed its division. 
Every new cell metabolizes, grows and develops. Throughout its life, it accumulates all of 
the necessary ingredients that are required for cell division. Once all of the ingredients are 
ready, the cell divides, and the cycle continues. Progression through the cell cycle is a 
highly regulated mechanism, and it is manned by key transition points which are called by 
checkpoints. The checkpoint allows or prohibits or passage into the next stage. These 
checkpoints make sure that the cell has acquired all of the necessary cellular components, 
and that all of the components are functional before allowing it to move onto the next stage. 
Any defect in these checkpoints can lead to unregulated cell growth which is seen in some 
cancers. 
  
The cell cycle majorly composes of two phases; interphase and mitotic phase. Mitotic 
phase is the period of active cell division. Interphase precedes M phase and is a preparatory 
phase.  M phase includes the division of the nucleus, also called as Karyokinesis, and the 







It is the longest period of the cell cycle, during this phase, DNA is synthesized, RNAs and 
proteins are produced, and energy reserves are built up. By convention interphase is divided 
into three sub-phases; Gap1 (G1) phase, Synthesis (S) phase, and Gap2 (G2) phase. 
 
G1 phase the cell grows in size and the proteins necessary for cell division are synthesized.  
Near the end of the G1 phase, G1/S checkpoint makes sure that all of the necessary 
enzymes for the replication of DNA are present. After this checkpoint is passed, the cell is 
committed to dividing.  Some cells before reaching G1/S checkpoint enter a G0 phase. It 
is a non-dividing phase of cell cycles. Cells in the G0 phase remain stable and maintain 
constant size. However, in certain conditions, they can re-enter the G1 phase. 
  
After the G1 phase, the cell enters the S phase (synthesis phase). In this phase the 
chromosomes duplicate. As a result at the end of this phase, each chromosome is composed 
of two chromatids. 
  
After the S phase, the cell enters the G2 phase, where other necessary biochemical events 
take place. At the climax of the G2 phase, there is an critical checkpoint- G2/M checkpoint. 
The cell will pass through this checkpoint if and only if the cell is undamaged. The presence 
of any damaged DNA inhibits the activation of proteins that are necessary for mitosis. After 
G2/M checkpoint the cell is ready to divide and enters M phase. However, in a cancerous 
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M-phase is the part of the cell cycle where the cell separates and undergoes division. M-
phase is divided into five stages; Prophase, Prometaphase, Metaphase, Anaphase, and 
Telophase (Pierce B.A, 2014). 
 
1.4.2 Cyclin E and CDK2 
  
In a normal cell, the progression through the cell cycle is a highly regulated process through 
which homeostasis in the cell number is maintained. Among other mechanisms, cell 
utilizes multiple checkpoints to control cell growth. These checkpoints are set up at various 
points throughout the cell cycle. These checkpoints regulate the passage of cell from one 
phase to the next.  Cancer cells exhibit a dysregulation in this process. This may result in 
an increased number of cells and rapid tumor growth (Pierce B.A, 2014). 
 
Cyclins and cyclin-dependent kinases act a check-points throughout the cell cycle. Cyclin 
proteins have two subunits, a catalytic subunit, and a regulatory subunit. The regulatory 
subunits are activated by Cyclin-dependent Kinases (CDKs). Once activated the catalytic 
part of cyclin protein becomes active and exhibits its downstream effects (Hwang & 
Clurman, 2005). CDKs remains more or less constant throughout the cell cycle whereas 
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the level of Cyclins fluctuates depending on the stage of the cell cycle. A preceding cyclin 
promotes the production of the cyclin next in line. 
 
Cyclin E is one such cyclin protein. It acts as a gatekeeper and controls the transition of the 
cell from G1 phase to S phase of the cell cycle. CDK2 binds with Cyclin E to forms A 
CyclinE-CDK2 complex. Activated CyclinE-CDK2 complex phosphorylates 
Retinoblastoma (Rb) to promote G1 progression. Hyperphosphorylated Rb promotes E2F 
transcription. This leads to the expression of genes that drive S-phase’s initiation and 
progression (Siu, Rosner, & Minella, 2012). 
 
The periodicity in the activity of Cyclin E -CDK2 complex is a result from multiple factors 
including  
 an abundance of Cyclin E levels,  
 binding of Cip/Kip CDK inhibitors and, 
 modification of CDK2 behavior by inhibiting and activating 
phosphorylation.  
 
These multiple layers of control ensure proper regulation of Cyclin E activity. In contrast, 
CyclinE-CDK2 activity is often dysregulated in cancer cells, and this is likely to contribute 
to the development of cancer. It is proposed that activation of cyclin E expression in excess 
may be a product of dysfunctional regulatory mechanism rather than a mutation in Cyclin 
E itself (Hwang & Clurman, 2005). 
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Hence, there is a high probability that a more rapidly progressing tumor will express a 
greater amount of Cyclin E expression. In this rapidly progressing tumor higher cyclin E 
production will facilitate the cancer cell to quickly transition G1 phase to S phase of the 
cell cycle. 
 
Cyclin-dependent Kinases (CDKs) are serine/threonine protein kinases. They elicit their 
enzymatic reaction with the help of a separate cyclin subunit. In addition to playing an 
essential role in cell division, they also play a key role in modulating transcription in 
response to extra and intracellular cues. Hence can be divided into two major subfamilies 
as dictated by the above properties. CDK1, 2, 4, and5 are related to cell cycle whereas 




1.5.1 A brief introduction to apoptosis 
 
The role of apoptosis in normal physiology is opposite to that of mitosis but has a 
complementary role in the development. Cancer is often seen where the cell cycle 
mechanism is out of control resulting in continuous proliferation, but it must be 
remembered that apoptosis plays a crucial role as well. It is often found that in most of the 
cancer cases the increased proliferative ability is compounded with a failure of apoptotic 
mechanisms. 
  
Apoptosis is often referred to as programmed cell death. Apoptosis is a natural process that 
occurs during development and serves a homeostatic mechanism to maintain a proper 
number of cells. It sometimes also occurs as a form of defense mechanism. A variety of 
conditions can trigger apoptosis. Genetically determined events being one of the prime 
examples. Apart from its irradiation, drugs, steroids, etc. may also lead up to this event. At 
low doses, noxious stimuli like heat, hypoxia, anti-cancer drugs, etc. can induce apoptosis. 
However, these same stimuli at higher dosage produce necrosis. Apoptosis is an energy-
dependent process. It is mediated through cysteine proteases called a Caspases. Activation 







During the process of apoptosis, the cell undergoes numerous changes. Cell shrinkage and 
pyknosis are perhaps the most easily witnessed phenomenon. Apoptotic cells grow smaller 
in size. The cytoplasm becomes dense, and all the organelles are tightly packed together. 
There is an extensive blebbing of the plasma membrane. This followed by karyorrhexis 
and separation of cell fragments into smaller apoptotic bodies. These apoptotic bodies 
contain densely packed organelles. The integrity of the organelles is well maintained in 
these bodies. These apoptotic bodies are usually then phagocytosed by the nearby 
macrophages. Macrophages that engulfs these apoptotic bodies are called as tangible body 
macrophages. Interestingly, though apoptosis involves macrophages, it is not an 
inflammatory process. This is because cell undergoing apoptosis do not release their 
cellular constituents into the surrounding, the remnants are quickly removed, and the 
engulfing cells do not produce any inflammatory cytokines (Kerr, Wyllie, & Currie, 1972). 
  
1.5.3 Morphological Changes During Necrosis 
  
Necrosis is often associated with cell swelling as opposed to cell shrinkage as seen in the 
case of apoptosis. Necrotic cells form cytoplasmic vacuoles and are associated with 
distended endoplasmic reticulum and formation of cytoplasmic blebs. The mitochondria 
are often swollen or ruptured. Ribosomes are detached. There is a summary disruption of 
the membrane of the organelle and the cell. This results in spilling of the inner contents of 
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the cells into the surrounding tissues. This triggers an inflammatory reaction (Majno & 
Joris, 1995) 
 
1.5.4 Apoptosis versus Necrosis 
  
Necrosis is a toxic process and follows the energy-independent mode of death. Necrosis is 
an uncontrolled, and passive process. It usually affects a large field of cells either directly 
or indirectly. Apoptosis, on the other hand, is a much more controlled process. It is energy 
dependent and affects only a limited cluster of cells (Majno & Joris, 1995). 
  
During the process of apoptosis, there is an externalization of residue on the apoptotic cells 
which can be detected by Annexin V. A similar phenomenon also occurs in necrotic cells. 
Therefore, cells are usually labeled with membrane impermeable nuclei dye like propidium 
iodide. Propidium Iodide fails to label apoptotic cells because of membrane integrity of the 
apoptotic bodies. However, this is not the case with necrotic cells. Their disrupted cell 
membrane allows the Propidium Iodide to enter label the nuclear material (Elmore, 2007)  
 
1.5.5 Mechanism of Apoptosis 
 
1.5.5.1 Intrinsic Pathway 
 
There are two main apoptotic pathways: the extrinsic and the intrinsic pathways. The 
intrinsic pathway is mediated by mitochondria and is regulated by the BCL-2 family. The 
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BCl-2 family consists of three subfamilies: proapoptotic BH3-only members, proapoptotic 
effector molecules (Bax and Bak), and antiapoptotic BCl-2 family proteins. In a healthy 
cell, Bax/Bak keep a check on the antiapoptotic BCL2. 
  
In the presence of an apoptotic stimulus, there is an upregulation of BHC3 protein. BHC3 
protein in turns promotes the release of cytochrome c through Bak and Bax.  Cytochrome 
along with Apaf-1 form an apoptosome. Binding of Cytochrome c to Apaf-1 replaces ADP 
with dATP. This complex recruits procaspase 9 which undergoes autocatalytic cleavage. 
The activated Caspase 9, in turn, activates Caspase 3. 
  
 The second group of apoptotic proteins called AIF, which are expressed at many later 
stages when the cell has committed itself to die is released from the mitochondria. After its 
release, the protein translocates itself to the nucleus of the cell where it causes the 
fragmentation and condensation of the DNA. Similar actions are produced by 
Endonuclease G and CAD protein. However, AIF and Endonuclease G function through a 
caspase-independent pathway whereas CAD is translocated inside the nucleus after it is 
cleaved by Caspase 3 (Elmore, 2007). 
1.5.5.2 Extrinsic Mechanism 
  
Extrinsic mechanism leads to the activation of a “Death receptor.” They have a cysteine-
rich extracellular portion and 80 amino acids long intracellular component called as death 
domain (Ashkenazi & Dixit, 1998). The death domain is responsible for transferring the 
death signal from outside the cell to its inside. TNF receptor is a classic example of a death 
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receptor. On binding with TNF ligand, the TNF receptor is activated to bind with adapter 
protein Tumor Necrosis factor receptor type-1 associated protein with death domain protein 
(TRADD), which allows the recruitment of caspase 8 resulting in cell apoptosis (Elmore, 
2007). 
  
1.5.5.3 A Gist of Caspase Activity 
  
Whether it be an extrinsic or intrinsic mechanism of apoptosis both of the process 
converges on the activation of Caspase. There are 13 different types of caspase molecules. 
They have been broadly grouped into executioner caspases and initiator caspases. Once the 
executioner caspases are activated by initiator caspase (Caspase-8, 9 and 10), they start 
degrading nuclear and cytoplasmic proteins. In apoptotic cells, caspase 3 activates CAD 
by cleaving ICAD. CAD then degrades the DNA within the nucleus and causes chromatin 
condensation. Caspase 3 cleaves Gelsolin protein. Cleaved gelsolin fragments, in turn, 
cleaves actin in a calcium-independent manner. This results in the disruption of the 







Porphyromonas gingivalis infection promotes cancer cell viability by enhancing cell 
proliferation, and reducing chemotherapy drug-induced apoptosis in ESCC.
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ATCC Pg33277 was purchased from the American Type Culture Collection (Manassas, 
VA) and maintained as frozen stocks. P. gingivalis was grown in Gifu anaerobic medium 
(GAM; Nissui Pharmaceutical, Tokyo, Japan). P. gingivalis was grown under anaerobic 
conditions (80% N2, 10% H2, and 10% CO2) at 37
oC in a Coy Laboratories Anaerobic 
chamber (Grass Lake Charter Township, MI). Growth was monitored by tracking optical 




Human-derived esophageal squamous cell carcinoma cell line (EC9706; NE3; KYSE-30; 
KYSE-70) was maintained as a frozen stock. They were grown in RPMI 1640 (Gibco® 
RPMI 1640 Cat. No. 21870-076) supplemented with 10% heat-inactivated Fetal Bovine 
serum (Atlanta Biologicals Cat No. S11150H), 1% Penicillin (10,000 units/ml) and 
Streptomycin (10,000 g/ml) (Gibco® Pen-Strep); 20mM HEPES (4-(2-Hydroxyethyl) 
piperazine-1-ethanesulfonic acid) buffer (Cellgro Cat. No. 25-060-CI), 20 mM sodium 
bicarbonate (Cellgro Cat. No. 25-035-CI), 1mM Sodium Pyruvate (Cellgro Cat. No. 
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25000-CI), 50M 2-mercaptoethanol (Sigma Aldrich Cat No M7522) and MMP which 
was filtered and stored at 4°C. Cells were maintained at 37.5°C in a humidified aerobic 
incubator (Sheldon Manufacturing, Inc.) at 5% CO2. When cells were incubated with 
Porphyromonas gingivalis penicillin was not added to the medium. 
 
Different cell lines represented different differentiation levels. EC9706 is a poorly-
differentiated cell line. NE3 are immortalized esophageal epithelial cells that can serve as 
a cancer study model (Zeng et al., 2016). KYSE-30 is a well-differentiated ESCC cell 
which was obtained from a tumor in the middle third of the esophagus which extended 
beyond adventitia to invade surrounding structures. The patient did not receive any prior 
treatment. KYSE-70 is a poorly-differentiated cell line that was obtained from a tumor 
from the middle third of the esophagus. It extended into the muscularis propria of the 
esophagus. The patient did not receive any prior treatment (Shimada, Imamura, Wagata, 




Paclitaxel: Also known as Taxol, it was approved as a chemotherapeutic agent in 1992 by 
US FDA. It is isolated from Taxus brevifolia tree and belongs to the family of microtubule 
inhibitor. Hence it prevents the metaphase-anaphase transition. They are also believed to 
have anti-angiogenic effects (Khanna, Rosenberg, & Vail, 2015). Paclitaxel for this project 
was sourced from Sigma Aldrich (Cat, No. T1912). 
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Cisplatin: Also known as cisplatinum or cis-Diamminedichloroplatinum (II) is a 
chemotherapeutic agent. It was first synthesized by M. Peyrone in 1844. Later in 1960 
Rosenberg et al. observed its ability to inhibit division in E. coli. It was approved for use 
in 1978 by the FDA. It causes DNA damage and interferes with DNA repair leading to 
apoptosis.  However, it commonly induces drug resistance and has several side effects 
(Dasari & Tchounwou, 2014). Cisplatin for this project was sourced from Sigma Aldrich 
(Cat. No. 11343557). 
 
5FU: 5 Flurouracili, a fluoropyrmidine, is used as the chemotherapeutic agent. It 
principally acts as thymidylate synthase inhibitor. By blocking the enzyme it prevents the 
synthesis of thymidine indirectly preventing DNA synthesis during S-phase (Focaccetti et 
al., 2015). 5FU for this project was sourced from Sigma Aldrich (Cat, No. F6627). 
 
2.3 Bacterial Invasion Assay 
 
P. gingivalis invasion into EC9706 cell line was detected using Leica TCS SP8 confocal 
laser scanning microscopy platform. P. gingivalis was labeled using Rabbit anti-Pg33277 
primary antibody and AlexaFluor594 Goat anti-rabbit secondary antibody. Actin and DNA 
were labeled using ActinGreen™ 488 ReadyProbes™ Reagent, and DAPI proLong gold 





2.4 MTT Proliferation Assay  
 
Vybrant MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) Cell 
Proliferation Assay Kit was utilized to determine the viability of EC9706 cell lines. An 
MTT assay involves the conversion of water-soluble MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) into an insoluble formazan salt.  The formazan salt is 
then solubilized by SDS (sodium dodecyl sulphate), and the concentration is determined 
using optical density at 570nm. Viable cells can convert MTT to a formazan salt thereby 
indicates towards the number of cells. 
 
2.5 CCK-8 Proliferation Assay   
 
CCK-8, with 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5(2,4-disulphophenyl)-2H-
tetrazolium, monosodium salt, as an active component, allows more sensitive colorimetric 
assays for the determination of cell viability when compared with other tetrazolium salts. 
The CCK-8 test uses a water-soluble Tetrazolium salt that is reduced by dehydrogenase 
activity in the cell to produce a yellow colored formazan dye which is soluble in tissue 
culture media. The amount of formazan dye produced is directly proportional to the number 
of living cells. The concentration is determined using optical density at 450nm (“Dojindo 





EdU Cell Cycle Imaging Assay 
 
Click-iT EdU Imaging kit from ThermoFisher scientific was utilized for cell cycle analysis. 
EdU (5-ethynyl-2’-deoxyuridine) is a nucleoside analog of thymidine and can be 
incorporated into the DNA during S-phase (DNA synthesis). The alkyne present in the EdU 
reacts with azide portion of Alexa Fluor dye through a copper catalyzed covalent reaction. 
Samples were fixed using 4% formaldehyde and then permeabilized with Triton X-100. 
Treatment with Triton X-100 allow the EdU to gain access to the DNA. Samples were 
incubated with EdU. Alexa Fluor azide 647 was utilized to measure the incorporated EdU 
using a Leica SP8 confocal inverted fluorescence microscope. 
 
2.6 Western Blot  
 
Samples were moved to on to the ice and washed with ice cold PBS. Cells were then lysed 
using RIPA buffer supplemented with EDTA, a phosphatase inhibitor, and a protease 
inhibitor. Lysate was homogenized by passing it through a sterile disposable insulin 
syringe. The lysate was centrifuged at 13,000 RPM for 15 min at 4C. The pellet was 
discarded, and the lysate was aliquoted. 
 
Protein concentration was estimated using Pierce BCA Protein Assay kit. Dilution of each 
sample (1:10) were incubate in a 96 well plate with 50l of reagent in a 1:1 ratio. Sample 
was incubated in dark for 1 hour. The optical density was then read at 562nm in a 
spectrophotometer and the protein concentration is estimated 
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Proteins are denatured at 70C for 15 minutes along with Sample reducing buffer buffer 
and LDS Sample buffer. The protein samples were then separated based on their molecular 
weight using Novex NuPage™ 4-12% Bis-Tris Gel and subsequently electrophoretically 
transferred onto a polyvinylidene difluoride membrane. Thus, the obtained membrane is 
blotted with 5% non-fat milk, washed with Tris-buffered solution supplemented with 0.1% 
Tween 20 (TBS-T) and then probed with the Primary antibody at concentration suggested 
by the manufacturer. The membrane is treated with HRP-conjugated secondary antibody. 
Chemiluminescent detection is performed, and the image will then be captured using 




 Transfection was performed to knockdown Cyclin E and CDK2 genes. siRNA was 
purchased from Dharmacon. Lipofectamine RNAiMAX Transfection Reagent in 
OptiMEM media is used to for transfection. Cell were transfected after reaching 60% 
confluency according to the protocol provided by the manufacturer. The accuracy of 
transfection was confirmed using western blot 
 
2.8 Statistical analysis:  
 
Data were using GraphPad PRISMTM (InStat v3.10 program; GraphPad Inc, San Diego 
California USA) software and appropriate tests were performed to establish statistical 
significance was set at <0.05. 
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3.1 P. gingivalis Can Invade EC-9706 Cells 
 
 
Figure 2: Confocal Image showing P. gingivalis invasion in (A) uninfected EC-9706 cells 
(control) and (B) EC-9706 infected with Porphyromonas gingivalis at two different time 
points of 6 hrs. and 24 hrs. Arrow points at P. gingivalis. The green color represents the 
























Figure 3: 3D restructuring of the confocal image showing P. gingivalis invasion in (A) 
uninfected EC-9706 cells (B) EC-9706 infected with P. gingivalis. The green color 
represents the actin cytoskeleton. The red color represents P. gingivalis. The green color 




Figure 4: Graph showing the ratio of Alexa Fluor 594 positive bacteria (red) containing 
live cell to the total live cell present in uninfected/unstimulated EC-9706 cells and in EC-
9706 (0.5 x 105cell/well) infected with P. gingivalis ATCC 33277(MOI 10) at 6 hrs. and 24 
hrs. Data presented with the mean ± standard error. 
 
To examine if P. gingivalis can invade ESCC cell in vitro we performed bacterial invasion 
assay. EC9706 (0.5 x 105/well) were incubated overnight in a 12 well plate. Afterwards, 
they were treated with P. gingivalis ATCC 33277 at MOI=10 for 8 hours. Cells were 
washed with PBS and fixed in 4% formaldehyde for 24hrs. Cells were incubated with 
Rabbit Anti-P. gingivalis ATCC 33277 antibody (1:1000) overnight. Samples were 
incubated with Goat anti-rabbit Alexa Fluor 594 for 1 hour. Samples are then washed and 
are stained with ActinGreenTM 488 ReadyProbes reagent for 30 minutes. Mounted on glass 
slides using ProLong Gold Antifade reagent with DAPI (4′6-diamidino-2-phenylindole) 
mounting medium prior to imaging with a Leica SP8 confocal inverted fluorescence 
microscope. Random 10 field of views were chosen. Cells with P. gingivalis in them were 
manually counted. Differences in the infected and uninfected group were determined by 
unpaired T-test (InStat version 3.10; GraphPad Inc, San Diego California USA). We found 
* *
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that P. gingivalis was successfully be able to reach inside the cell. Further, this was a time 
dependent phenomenon as more P. gingivalis was found within the cell at 24 hours when 
compared to 6 hours. 
 
3.2 P. gingivalis Promotes Proliferation in ESCC Cells 
 
 
Figure 5: Graph showing the percentile of cell proliferation in P. gingivalis infected group 
when compared to uninfected group measured through MTT proliferation assay at 562 nm. 
NE3, KYSE 30, KYSE 70 and EC9706 cell lines (5000 cell/well) were infected by 
Porphyromonas gingivalis ATCC 33277 (MOI 10) Data are presented as the mean ± 
standard error of three individual experiments. Data are presented as the mean ± standard 
error of three individual experiments.  
 
To examine if P. gingivalis can promote proliferation in ESCC cells we performed an MTT 
proliferation assay. NE3, KYSE-30, KYSE-70 and EC-9706 (5000 cells/well) cell and 













MTT Cell Proliferation Assay
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gingivalis ATCC 33277 at MOI=10 for 48 hrs. VybrantTM MTT Cell Proliferation Assay 
Kit was utilized to determine the viability of ESCC cell lines. MTT from the kit was added 
and the cells were incubated for 4 hours, followed by another 4 hours of incubation with 
SDS-HCl solution. Optical Density was measured at 562nm using spectrophotometer. 
Differences in the infected and uninfected group were determined by unpaired T-test 
(InStat version 3.10; GraphPad Inc, San Diego, California, USA). We found that 
Porphyromonas gingivalis ATCC 33277 significantantly increased proliferation in NE3, 
KYSE-30 , KYSE-70 and EC-9706 cell lines 
 




Figure 6: Graph showing the results for CCK8 proliferation assay at 450 nm for various 
concentration of P. gingivalis ATCC 33277.  
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To examine if Porphyromonas gingivalis can by itself influence a Tetrazolium salt-based 
proliferation assay we utilized different concentrations Porphyromonas gingivalis and 
subjected it to CCK-8 proliferation assay. Porphyromonas gingivalis ATCC 33277 was 
added to 96 well plate in different concentrations. CCK-8 reagent (10l) was added to the 
sample. The plate was incubated for 4 hours after which it was read at 450nm using a 
spectrophotometer. The graph plotted using the optical density values obtained from the 
assay (InStat version 3.10; GraphPad Inc, San Diego, California, USA). Statistical analysis 
could not be performed due to the absence of replicates. This experiment was performed 
as a measure of added control. We utilized optical density as a measure because of the ease 
of translatability to other experiments. 
  
3.4 P. gingivalis Promotes Passage of ESCC Cells to S-Phases 
 
(A)                                                      (B) 
Figure 7: Confocal image showing (A) Uninfected/unstimulated EC-9706 cell nuclei 
(control) and (B) EC-9706 infected with Porphyromonas gingivalis. The blue of the 
nuclei is due to DAPI. The presence of pink in nuclei show EdU positive nuclei (Alexa 
Fluor 647) representing nuclei in S-phase 
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 Figure 8: Graph showing the percentile of EdU positive (Alexa Fluor 647 positive) stained 
cells (A) Uninfected/unstimulated EC-9706 cells (105 cell/well) (control) and (B) EC-9706 
(105 cell/well) infected with Porphyromonas gingivalis ATCC 33277 (MOI 10). Data 
presented with the mean ± standard error.   
 
To examine how Porphyromonas gingivalis promotes cell proliferation we decided to 
perform an EdU based cell cycle assay using Click IT EdU Imaging kit by ThermoFisher. 
EC-9706 (1x105 cells/well) cell incubated overnight in a 12 well plate. EC-9706 was 
infected with Porphyromonas gingivalis ATCC 33277 at MOI 10 and was incubated for 
20 hrs. 10µM Edu was added and was incubated for another 4 hours. Cells were fixed using 
4% formaldehyde for 24 hrs. Fixative agent was removed and cell were permeabilized with 
TritonX-100 for 30 minutes. Detergent was removed and Click-IT Alexa FluorTM EdU 
buffer was added and incubated in dark for 30 minutes. Imaging was done using a Leica 
SP8 confocal inverted fluorescence microscope. Differences in the infected and uninfected 
group were determined by unpaired T-test (InStat version 3.10; GraphPad Inc, San Diego, 
California, USA). We found that Porphyromonas gingivalis promoted S-phase transition 
in EC-9706 cell line 
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3.5 Infection of P. gingivalis Differentially Alters the Activity of ESCC Cells 
 
 
(A)                                                        (B) 
 
Figure 9: (A) Western blot showing Cyclins and CDK levels in P. gingivalis ATCC 
33277(MOI 10) treated EC-9706 (106 cell/well) at time points 30mins, 2hrs. and 4hrs; (B) 
A graph showing Cyclins and CDK levels in P. gingivalis ATCC 33277(MOI 10) treated 
EC-9706 (106 cell/well) at time points 30mins, 2hrs. and 4hrs. 
 
EC-9706 cells (1x106 cells/well) were seed into a 6-well plate and were incubated 
overnight. Samples were treated with P. gingivalis ATCC 33277 (MOI 10) for 30 minutes, 
2 hours and 4 hours. The uninfected group (4 hours) served as a control for this experiment 
Sample were lysed using RIPA buffer (5 mM EDTA; SIGMA proteinase inhibitor cocktail; 
SIGMA phosphatase cocktail 2 and 3 and PMSF). and protein was homogenized using a 
fine bore sterile insulin syringe. Gel electrophoresis was utilized to seperate the proteins 
based on their molecular weight. Proteins were then transferred to a PVDF membrane and 
was read using suitable antibodies on ImageQuantTM LAS 4000 mini (GE Healthcare). 
Statistical analysis could not be performed due to the absence of replicates. 
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Figure 10: Graph showing the result of CCK8 proliferation assay at 450 nm for P. 
gingivalis ATCC 33277 (MOI 10) treated, CDK2 knocked down EC9706 cells. Data 
presented with the mean ± standard error. Values are calculated by subtracting OD 450 
nm - OD 450 nm of media blank. Western Blot showing the expression of CDK2 protein in 
CDK2 knockdown sample 
 
We wanted to examine if CDK2 protein was involved in P. gingivalis mediated cell 
proliferation in ESCC cells. Hence, we conducted a transfection assay to knockdown 
CDK2 gene to decrease CDK2 production. EC9706 cells (7.5x105 cells/well) were seeded 
and were incubated overnight. Transfection was performed to knockdown CDK2 using 
siRNA was purchased from Dharmacon. Lipofectamine RNAiMAX Transfection Reagent 
in OptiMEM media is used to for transfection. After 8 hrs. the cells were infected with 
Porphyromonas gingivalis (MOI= 10:1) for 72 hrs. Medium was replaced every 24 hours 
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after transfection. After 72 hours CCK-8 Proliferation assay was utilized to estimate cell 
proliferation. Cells were incubated with CCK-8 reagent for 4 hours in dark. Optical density 
was measured at 450 nm using a spectrophotometer. Accuracy of the transfection was 
measured using western blot. Differences in the infected and uninfected group were 
determined by one-way ANOVA test with a post hoc Tuckey test (InStat version 3.10; 
GraphPad Inc, San Diego, California, USA). We found that P. gingivalis could not promote 
cell proliferation in EC-9706 cells if CDK2 gene was knockdown, when compared to its 
control group. 
 




Figure 11: Graph showing the result of CCK8 proliferation assay at 450 nm for P. 
gingivalis ATCC 33277 (MOI 10) treated, Cyclin E knocked down EC9706 cells. Data 
presented with the mean ± standard error. Values are calculated by subtracting OD 450nm 
- OD 450nm of media blank. Western Blot showing the expression of Cyclin E protein in 
Cyclin E knockdown sample 
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We wanted to examine if Cyclin E protein was involved in P. gingivalis mediated cell 
proliferation in ESCC cells. Hence, we conducted a transfection assay to knockdown 
Cyclin E gene to almost eliminate Cyclin E production. EC9706 cells (7.5x105 cells/well) 
were seeded and were incubated overnight. Transfection was performed to knockdown 
CDK2 using siRNA was purchased from Dharmacon. Lipofectamine RNAiMAX 
Transfection Reagent in OptiMEM media is used to for transfection. After 8 hrs. the cells 
were Infected with Porphyromonas gingivalis ATCC33277 (MOI= 10:1) for 72 hrs. 
Medium was replaced every 24 hours after transfection. CCK-8 Proliferation assay was 
utilized to estimate cell proliferation. Cells were incubated with CCK-8 reagent for 4 hours 
in dark. Optical density was measured at 450 nm using a spectrophotometer. Accuracy of 
the transfection was measured using western blot. Differences in the infected and 
uninfected group were determined by one-way ANOVA test with a post hoc Tuckey test 
(InStat version 3.10; GraphPad Inc, San Diego, California, USA). We found that P. 
gingivalis could not promote cell proliferation in EC-9706 cells if Cyclin E gene was 









3.8 Infection of P. gingivalis induces apoptosis resistance in EC-9706 upon treatment 
with different chemotherapy drugs 
 
 
Figure 12: Image showing the results of flow cytometry in EC9706 on treatment with 
neoadjuvant drugs (Paclitaxel= 1M, Cisplatin=4 M, 5-FU=2.5 m) in P. gingivalis 
ATCC 33277 (MOI 10) infected samples. Graphical representation of the flowcytometry 
Data are presented as the mean ± standard error of three individual experiments.  
 
We wanted to examine if P. gingivalis can promote apoptosis resistance in chemotherapy 
drug treated ESCC cells. Esophageal squamous carcinoma cells (EC-9706) were treated 
EC-9706
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with P. gingivalis ATCC 33277 (MOI=10) for 24 hours followed by treatment with 
different chemotherapeutic agents (Paclitaxel, Cisplatin, 5-FU). Unstimulated group, 
Porphyromonas gingivalis treated only group and Chemotherapeutic treated only group 
served as controls for this experiment (Paclitaxel= 1M, Cisplatin=4 M, 5-FU=2.5 m). 
Flow cytometry was utilized to measure the total number of apoptotic cells using Annexin 
V and Propidium Iodide as a marker. Data was quantified and is graphed as a percentile of 
apoptotic cells. Differences in the infected and uninfected group were determined by one-
way ANOVA test with a post hoc Tuckey test (InStat version 3.10; GraphPad Inc, San 
Diego, California, USA). We found that in all the groups P. gingivalis promoted apoptosis 
resistance in EC-9706 cells. Apart from this we also observed difference between other 













3.9 Infection of P. gingivalis induces apoptosis resistance in different esophageal 




Figure 13: Graph showing the apoptosis resistance in NE3 KYSE-30 and KYSE-70 on 
treatment with neoadjuvant drugs Paclitaxel (1m) in P. gingivalis ATCC 33277 (MOI 10) 
infected samples. Data are presented as the mean ± standard error of three individual 
experiments.  
 
ESCC cells (NE3, KYSE-30, KYSE-70) were treated with P. gingivalis for 24 hours 
followed by treatment with a chemotherapeutic agent (Paclitaxel). Unstimulated group, 
Porphyromonas gingivalis treated only group, and Chemotherapeutic treated only group 
served as a control for this experiment. MTT colorimetric assay was utilized to measure 
the total number of viable cells. Data was quantified and is graphed as a percentile of 
apoptotic cells. Differences in the infected and uninfected group were determined by one-
MTT Cell Proliferation Assay
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way ANOVA test with a post hoc Tuckey test (InStat version 3.10; GraphPad Inc, San 
Diego, California, USA). We found that in all the groups P. gingivalis promoted apoptosis 
resistance in against Paclitaxel. Apart from this we also observed difference between other 
sample of the group which is discussed in detail in the discussion section. 
 




Figure 14: Western blot showing the Caspase 3 activity in P. gingivalis ATCC 33277 (MOI 
10) infected EC9706 cells (106 cells/well) at time points 12hrs. and 24hrs.  
 
To examine if P. gingivalis can affect caspase 3 production in ESCC cell we looked at the 
Caspase 3 protein levels under different treatments time points using western blot. EC-
9706 cells were treated with P gingivalis for 12- and 24-hour time periods. The uninfected 
group served as a control for this experiment. Western blot was utilized to measure the 
changes in Caspase-3 levels. Sample were lysed using RIPA buffer (5 mM EDTA; SIGMA 
proteinase inhibitor cocktail; SIGMA phosphatase cocktail 2 and 3 and PMSF). and protein 
was homogenized using a fine bore sterile insulin syringe. Gel electrophoresis was utilized 
to separate the proteins based on their molecular weight. Proteins were then transferred to 
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a PVDF membrane and was read using suitable antibodies on ImageQuantTM LAS 4000 







Previous studies have shown that P. gingivalis preferentially invade oral squamous cell 
carcinoma cells when compared to surrounding tissue. P. gingivalis promotes proliferation 
and epithelium-to-mesenchyme transition (EMT) in OSCC. It implies that P. gingivalis has 
the potential to transform OSCC to a more aggressive variety. Since the oral mucosa and 
the proximal part of esophageal lining are similar, it is entirely plausible that P. gingivalis 
can produce similar effects in ESCC. Porphyromonas gingivalis was found in the distant 
tissue of gastrointestinal-tract like colon and stomach tissue. Hence, more proximal tissue, 
like the esophagus, to the natural niche of Porphyromonas gingivalis is more likely to be 
infected. 
  
In their study, Gao et al. showed that P. gingivalis preferentially localized itself in the 
cancerous tissue when compared to surrounding normal and dysplastic tissue. The study 
showed a positive correlation between P. gingivalis and poor survival rate. However, this 
study failed to explain why patients who are positive for P. gingivalis have poorer survival 
rates (Khanna, Rosenberg, & Vail, 2015). 
 
 In our first experiment, we utilized EC9706, an ESCC cell line, to see if Porphyromonas 
gingivalis retains its invasive capabilities in vitro. We chose P. gingivalis ATCC 33277 in 
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this project, because in Gao et al. study the P. gingivalis antibody that was used on the 
esophageal tissue, was directed against P. gingivalis ATCC 33277. We set up the 
experiment at two different time points one at 6 hours and another at 24 hours. We planned 
to examine if Porphyromonas gingivalis invasion was time dependent. Our results show 
that Porphyromonas gingivalis was able to successfully invade EC9706 cells in vitro. 
Statistical analysis showed that Porphyromonas gingivalis invaded the cells in a time-
dependent manner with a 24 hours cell group showing higher invasiveness when compared 
to 6 hours group. We confirmed the invasion of EC9706 by Porphyromonas gingivalis by 
the 3D rendering of the obtained images. However, it must be noted that mere the presence 
of bacterium within the cell does not confirm active invasion. Further, experiments are 
needed to determine that if P. gingivalis invaded these cells or were engulfed by the process 
of phagocytosis. A P. gingivalis mutant with a defective fimA gene can be used as a 
control for this experiment to show active invasion process. Fimbriae have been shown to 
critical for P. gingivalis. We expect that fimA mutant will show sub-par invasiveness.  
 
After confirming that Porphyromonas gingivalis can invade EC 9706 cells in vitro we went 
ahead to set up MTT proliferation assay to see if Porphyromonas gingivalis promotes 
proliferation of ESCC cells. We preferred using MTT proliferation assay over CCK-8 
proliferation assay as it is less sensitive and requires a significant change to register a 
difference. By using this assay, we hoped to achieve more reliable results.  In this 
experiment, we utilized 4 different cell lines of ESCC namely any NE3, KYSE30, 
KYSE70, and EC9706. The rationale behind using different cell lines was to see if the 
proliferative ability of Porphyromonas gingivalis is true across multiple cell lines. These 
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cell lines are of different differentiation level. By utilizing different cell lines, we aimed to 
mimic real-life scenario. We infected half of the cells with Porphyromonas gingivalis 
ATCC 33277 while the other half remained uninfected and served as the control for the 
experiment. We found that Porphyromonas gingivalis infected ESCC cells and showed a 
significant increase in proliferation.  This experiment shows that Porphyromonas 
gingivalis promotes proliferation of ESCC cells and this proliferative potential is true for 
multiple ESCC cell lines. However, it is be noted that this experiment did not have a control 
for a Gram-negative anaerobic bacterium. Further experiments are needed to done to see if 
this phenomenon is exclusive to P. gingivalis. These experiments are important as there is 
an emerging evidence that Fusobacterium nucleatum, a Gram-negative periodontal 
pathogen, can promote tumorigenesis through cell proliferation in colorectal cancer and 
OSCC (Binder Gallimidi et al., 2015; Mima et al., 2016; Shang & Liu, 2018).  
 
MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) Proliferation Assay 
is a tetrazolium-based assay. It relies on the conversion of the tetrazolium salt into insoluble 
purple colored formazan. This reaction relies on an NADPH dependent oxidoreductase 
enzyme. It is often used to determine cell proliferation. Since it is a quick and reliable 
method we decided to measure if P. gingivalis induced proliferation of ESCC cells.  
 
However, we did not find any study that showed that if Porphyromonas gingivalis on its 
own can reduce tetrazolium salt to formazan. In case Porphyromonas gingivalis did have 
this ability, it would have produced overestimation of the number of cell in Porphyromonas 
gingivalis infected group. Hence, to determine if Porphyromonas gingivalis can 
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significantly affect the results, we measured the ability of Porphyromonas gingivalis to 
convert tetrazolium to formazan. We used a more sensitive CCK-8 assay for this procedure. 
Unlike MTT Proliferation assay CCK-8 is faster and more sensitive. We used this assay 
instead of MTT proliferation assay to record even a minimalistic change. Based on our 
understanding of Tetrazolium salts and Porphyromonas gingivalis we expected 
Porphyromonas gingivalis to reduce Tetrazolium salts to formazan salt. We found that 
Porphyromonas gingivalis has a minimal capability of converting tetrazolium salt to 
formazan. At a lower concentration of 105 cell, it produced no detectable change. Hence, 
the ability of Porphyromonas gingivalis to convert tetrazolium to formazan could have 
affected the results of the MTT proliferation assay. Further, it is to be noted that at higher 
concentration the sample appeared very cloudy which might have contributed to a sudden 
increase in optical density at higher values. This experiment served as an added control.  
 
Next, we wanted to see how Porphyromonas gingivalis promoted proliferation. We 
decided to look at cell cycle in general, and S-phase in particular. S-phase or the synthesis 
phase of cell cycle is when the DNA replicates itself. Thus, it marks the commitment of 
the cell to divide. For this experiment, we used Click IT EdU Imaging kit by ThermoFisher. 
We chose this test over well-established BrdU because of the three advantages that EdU 
offered a) simplicity b) reliability and c) lower complexity. We labeled uninfected EC9706 
cells and Porphyromonas gingivalis infected EC9706 cells with EdU to see the effects of 
Porphyromonas gingivalis on the phases of the cell cycle. During the S-phase of the cell 
cycle when the DNA duplicates, it allows the substitution of EdU into the DNA. Once 
incorporated it can be seen AlexaFluor 647. Cells in other phases of cell cycle do not allow 
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this addition due to the inaccessibility of DNA to EdU molecule. The final image shows 
unstained or EdU negative nuclei as blue due to DAPI while EdU positive nuclei show in 
pink color. Our results showed that Porphyromonas gingivalis significantly promotes S 
phase in ESCC cells when compared to the uninfected control group.  
  
Next, we infected EC9706 cells with Porphyromonas gingivalis ATCC 33277at an MOI 
10 at 3 different time points; 30 minutes, 2 hours, and 4 hours. For this experiment, we 
chose early time points to early influences of P. gingivalis on cell cycle. After which we 
ran a western blot of all 4 samples (3 infected groups plus1 controlled) to look at different 
cyclins and CDK protein levels. We chose to look at different cyclin and CDK proteins to 
have a better understand the early influences of P. gingivalis invasion into the cell which 
would not have been possible if we would have limited ourselves to S-phase related 
proteins. We observed a general upward trend in all the cyclins and CDK proteins. 
However, as it was a single blot and there were no replicates, we could not perform any 
statistical comparison. Thus, we cannot be conclusive in this regard. 
  
Based on our previous results, we expected to see a marked rise in cyclin E levels because 
Cyclin E is an important marker for S-phase. However, our results were not in line with 
our expectations. Though there was an increase in Cyclin D levels; levels of Cyclin E were 
more or less constant. In addition, we observed an increase in Cyclin A levels both of which 
are produced in S-phase after cell crosses G1/S phase guarded by Cyclin E. This anomaly 
can be explained by an increased productions p-CDK2. We believe that higher levels of 
the p-CDK2 push for increased in S-phase in spite of minimal changes in Cyclin E. We 
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speculate that the rise in p-CDK can be due to Cyclin A2 or loss of Cip/Kip CDK inhibitor. 
Another possibility can be that Cyclin E may peak at a different time point.  
  
Based on our previous results we speculated that Porphyromonas gingivalis promotes 
proliferation in ESCC cell line through Cyclin E-CDK2 mediated pathway. To confirm 
this, we performed transfection assay. In the first part of our experiment, we knocked down 
the CDK2 gene in the EC9706 cell line. After which we infected it with Porphyromonas 
gingivalis. We found that after CDK2 gene was knocked down Porphyromonas gingivalis 
was not able to promote proliferation in EC9706 cells. We repeated this experiment by 
knocking down Cyclin E to find similar results. We conclude that Porphyromonas 
gingivalis promotes proliferation in EC9706 cell line through Cyclin E-CDK2 mediated 
pathway. We think that by knocking down Cyclin E and CDK2 we prevented the formation 
Cyclin E-CDK2 complex which might have been playing a key role in Porphyromonas 
gingivalis induced proliferation. Another interesting observation was the knockdown 
samples a showed similar growth rate as an uninfected ESCC cell. 
  
In the second part of our experiment, we wanted to see if Porphyromonas gingivalis can 
promote apoptosis resistance in chemotherapeutically treated ESCC cells. To examine the 
apoptosis resistance of Porphyromonas gingivalis in chemotherapeutically cells, we treated 
EC-9706 cells lines with 3 neo-adjuvant chemotherapeutic drugs, namely, Paclitaxel, 
Cisplatin, and 5FU. The rationale behind selecting these drugs was that the National 
Comprehensive Cancer Network 2013 prescribed triple-drug therapy as a treatment against 
ESCC. In addition, these drugs have different mechanisms of action. Our flowmetry data 
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shows that Porphyromonas gingivalis promoted apoptosis resistance against all 3 
neoadjuvant drugs in the EC9706 cell line. During the process of apoptosis, 
phosphatidylserine is expressed over the cell membrane which can be detected by Annexin 
V dye. Hence, it serves as a marker for early apoptosis. However, in the case of necrosis 
and late apoptotic phase, the cell membrane integrity is lost. This allows PI dye to stain the 
nucleus. Hence, the cells that stain positive for both PI and Annexin V are necrotic or late 
apoptotic cells while the cells which stain only for Annexin V are early apoptotic cells. We 
also observed that in Paclitaxel group and 5-FU group Porphyromonas gingivalis 
significantly reduced the drug-induced apoptosis, but it still remained higher than cells that 
were not treated with a chemotherapy drug. This shows that Porphyromonas gingivalis 
diminishes the effects of Paclitaxel and 5-FU. However, the same thing cannot be said 
about Cisplatin. Porphyromonas gingivalis not only reduced the drug-induced apoptosis 
but brought it down to the level of Cisplatin negative samples. This is an important finding 
as it suggests Porphyromonas gingivalis not only diminishes but nullifies the effect of 
Cisplatin. Another interesting result was that Porphyromonas gingivalis did not lower the 
apoptosis below untreated group. In other words, antiapoptotic activity of Porphyromonas 
gingivalis was demonstrable only in the presence of chemotherapy drug. This suggests that 
Porphyromonas gingivalis may be interfering with the drug action. 
 
Next, we wanted to see if this apoptosis resistance is limited only to the EC9706 cell line 
or can be seen in other ESCC cell lines as well. To achieve this, we infected the following 
ESCC cell lines with Porphyromonas gingivalis NE3, KYSC30, KYSC70, and EC-9706 
and then treated with Paclitaxel. All the cell lines showed similar trends. The 
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Porphyromonas gingivalis infected group showed higher apoptosis resistance when 
compared to the uninfected control group. Also, Porphyromonas gingivalis infected group 
with Paclitaxel treatment showed significantly higher apoptosis than Paclitaxel negative 
groups.  It shows that Porphyromonas gingivalis promotes apoptosis resistance in multiples 
ESCC cell lines and though the difference is significant the difference is not overwhelming. 
Therefore, its biological relevance in patients is questionable. Also, according to the 
protocol developed by the National Comprehensive Cancer Network 2013 an ESCC patient 
is supposed to receive all the three drugs simultaneously. It will be interesting to see the 
effect of Porphyromonas gingivalis in the context of triple-drug therapy. 
  
In our final experiment, we wanted to if Porphyromonas gingivalis to look at the 
mechanism behind it. We set up the experiment at two different time points of 12 hours 
and 24 hours. We treated Porphyromonas gingivalis infected EC9706 with Paclitaxel. 
Caspase 3 plays a central role in the execution-phase and can be activated through both 
intrinsic as well as the extrinsic mechanism of apoptosis. Further, its cleaved products give 
an idea about the amount of apoptotic activity. We found that in Porphyromonas gingivalis 
infected EC9706 cell group lowered the production of Caspase 3. This may suggest a 
decrease in apoptotic activity. However, since this was performed over a single blot, we 
cannot it to be conclusive about it. This experiment has to be repeated to establish if there 




In all the above experiments, we have only compared Esophageal cancer cells. However, 
normal esophageal cells can be added to these experiments. P.gingivalis have been shown 
to cause similar effects in human immortalized gingival epithelial cells (HIGECs). We 
speculate that due to the similar nature of esophageal epithelium P.gingivalis might have 










Esophageal squamous cell carcinoma is highly debilitating and lethal disease. Almost 80% 
of its patients die within 5 years of their diagnosis. Studies have shown that Porphyromonas 
gingivalis further deteriorates the condition of these patients. This study shows how 
Porphyromonas gingivalis may be causing these effects and suggests that by improving 
oral hygiene and decreasing Porphyromonas gingivalis load in ESCC patients can help to 
increase patient’s survival.   
 
With further investigation and understanding the molecular mechanism by which 
Porphyromonas gingivalis exerts these changes, we will be able to develop targeted 
processes or drugs to inhibit the harmful effects of Porphyromonas gingivalis. 
Porphyromonas gingivalis specific antibiotics use as an adjunct to chemotherapy can be 
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